Transfusion Medicine Reviews
Volume 20, Issue 4 , Pages 259-272 , October 2006

Testing for Heparin-Induced Thrombocytopenia Antibodies

  • Theodore E. Warkentin

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Theodore E. Warkentin, MD, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, General Site, 237 Barton St. E., Hamilton, Ontario, Canada L8L 2X2.
    • ,
  • Jo-Ann I. Sheppard

References 

  1. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb. Haemost. 1998;79:1–7
  2. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In:  Warkentin TE,  Greinacher A editor. Heparin-induced thrombocytopenia. New York: Marcel Dekker; 2004;p. 53–106
  3. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb. Haemost. 1992;68:95–96
  4. Slungaard A. Platelet factor 4: A chemokine enigma. Int. J. Biochem. Cell. Biol. 2005;37:1162–1167
  5. Greinacher A, Potzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb. Haemost. 1994;71:247–251
  6. Greinacher A, Gopinadhan M, Guenther JU, et al. The molecular structure of the antigen in heparin-induced thrombocytopenia. [abstract] J. Thromb. Haemost. 2005;OR217
  7. Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703–1708
  8. Warkentin TE, Sheppard J-AI, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia. How much class do we need?. J. Lab. Clin. Med. 2005;146:341–346
  9. Aster RH. Drug-induced immune cytopenias. Toxicology. 2005;209:149–153
  10. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch. Pathol. Lab. Med. 2002;126:1415–1423
  11. Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J. Thromb. Haemost. 2006;4:281–282
  12. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: Laboratory studies. Blood. 1988;72:925–930
  13. Newman PM, Chong BH. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti–PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000;96:182–187
  14. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27–30
  15. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet. 1982;2:1246–1249
  16. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691–3699
  17. Warkentin TE, Sheppard JI. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: A comparison with standard platelet agonists. Platelets. 1999;10:319–326
  18. Chong BH, Murray B, Berndt MC, et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood. 1994;83:1535–1541
  19. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb. Haemost. 2005;94:132–135
  20. Denomme GA, Warkentin TE, Horsewood P, et al. Activation of platelets by sera containing IgG1 heparin-dependent antibodies: An explanation for the predominance of the FcγIIa “low responder” (his131) gene in patients with heparin-induced thrombocytopenia. J. Lab. Clin. Med. 1997;130:278–284
  21. Gruel Y, Pouplard C, Lasne D, et al. The homozygous FcγRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood. 2004;104:2791–2793
  22. Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med. 1997;127:804–812
  23. Warkentin TE. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin. Hematol. 1998;35(Suppl 5):17–25
  24. Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis and management. Br. J. Haematol. 2003;121:535–555
  25. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N. Engl. J. Med. 1987;316:581–589
  26. Blank M, Shoenfeld Y, Tavor S, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int. Immunol. 2002;14:121–129
  27. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood. 2001;98:1252–1254
  28. Khairy M, Lasne D, Brohard-Bohn B, et al. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Formation of leukocyte-platelet aggregates. Thromb. Haemost. 2001;85:1090–1096
  29. Khairy M, Lasne D, Amelot A, et al. Polymorphonuclear leukocyte and monocyte activation induced by plasma from patients with heparin-induced thrombocytopenia in whole blood. Thromb. Haemost. 2004;92:1411–1419
  30. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin. Thromb. Hemost. 2004;30:273–283
  31. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest. 2005;127(2 Suppl):35S–45S
  32. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In:  Warkentin TE,  Greinacher A editor. Heparin-induced thrombocytopenia. New York: Marcel Dekker; 2004;p. 271–311
  33. Warkentin TE, Hayward CP, Smith CA, et al. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J. Lab. Clin. Med. 1992;120:371–379
  34. Greinacher A, Michels I, Kiefel V, et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb. Haemost. 1991;66:734–736
  35. Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced antibodies: Validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb. Haemost. 1999;81:625–629
  36. Lee DH, Warkentin TE, Denomme GA, et al. A diagnostic test for heparin-induced thrombocytopenia: Detection of platelet microparticles using flow cytometry. Br. J. Haematol. 1996;95:724–731
  37. Amiral J, Vissac AM. Generation and pathogenicity of anti-platelet factor 4 antibodies: Diagnostic implications. Clin. Appl. Thromb. Hemost. 1999;5(Suppl 1):S28–S31
  38. Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion. 1994;34:381–385
  39. Visentin GP, Moghaddam M, Beery SE, et al. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J. Lab. Clin. Med. 2001;138:22–31
  40. Nagi PK, Ackermann F, Wendt H, et al. Protein A antibody-capture ELISA (PACE): An ELISA format to avoid denaturation of surface-adsorbed antigens. J. Immunol. Methods. 1993;158:267–276
  41. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb. Haemost. 1998;80:292–297
  42. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106:3791–3796
  43. Meyer O, Salama A, Pittet N, et al. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet. 1999;354:1525–1526
  44. Alberio L, Kimmerle S, Baumann A, et al. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am. J. Med. 2003;114:528–536
  45. Chilver-Stainer L, Lammle B, Alberio L. Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb. Haemost. 2004;91:276–282
  46. Eichler P, Raschke R, Lubenow N, et al. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br. J. Haematol. 2002;116:887–891
  47. Warkentin TE, Kelton JG. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In:  Bounameaux H editors. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker; 1994;p. 75–127
  48. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In:  Warkentin TE,  Greinacher A editor. Heparin-induced thrombocytopenia. New York: Marcel Dekker; 2004;p. 107–148
  49. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 1995;332:1330–1335
  50. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch. Intern. Med. 2003;163:2518–2524
  51. Amiral J, Wolf M, Fischer A, et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br. J. Haematol. 1996;92:954–959
  52. Lindhoff-Last E, Gerdsen F, Ackermann H, et al. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br. J. Haematol. 2001;113:886–890
  53. Vun CM, Evans S, Chesterman CN. Anti-PF4-heparin immunoglobulin G is the major class of heparin-induced thrombocytopenia antibody: Findings of an enzyme-linked immunofiltration assay using membrane-bound hPF4-heparin. Br. J. Haematol. 2001;112:69–75
  54. Greinacher A, Eichler P, Lietz T, et al. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood. 2005;106:2921–2922
  55. Martel N, Lee J, Wells PS. Risk of heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis. Blood. 2005;106:2710–2715
  56. Parody R, Oliver A, Souto JC, et al. Fondaparinux (ARIXTRA) is an alternative antithrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparin. Haematologica. 2003;88:ECR32
  57. Kuo KH, Kovacs MJ. Fondaparinux: A potential new therapy for HIT. Hematology. 2005;10:271–275
  58. Harenberg J, Jorg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica. 2004;89:1017–1018
  59. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: An overview. In:  Warkentin TE,  Greinacher A editor. Heparin-induced thrombocytopenia. New York: Marcel Dekker; 2004;p. 335–370
  60. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):311S–337S
  61. Warkentin TE. Management of heparin-induced thrombocytopenia: A critical comparison of lepirudin and argatroban. Thromb. Res. 2003;110:73–82
  62. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: A critical review. Arch. Intern. Med. 2004;164:361–369
  63. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 1996;101:502–507
  64. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am. J. Med. 1999;106:629–635
  65. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr. Hematol. Rep. 2003;2:148–157
  66. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J. Thromb. Haemost. 2006;4:759–765
  67. Lo GK, Warkentin TE. Towards a conceptual framework for diagnosis of heparin-induced thrombocytopenia (HIT). [abstract] Blood. 2005;106:359a
  68. Lillo-Le Louët A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J. Thromb. Haemost. 2004;2:1882–1888
  69. Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur. J. Haematol. 2006;76:420–426
  70. Mattioli AV, Bonetti L, Sternieri S, et al. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: Prevalence of thrombosis in a 1 year follow-up. Ital. Heart J. 2000;1:39–42
  71. Williams RT, Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/heparin antibodies. An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation. 2003;107:2307–2312
  72. Mascelli MA, Deliargyris EN, Damaraju LV, et al. Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. J. Thromb. Thrombolys. 2004;18:171–175
  73. Mascelli MA, Deliargyris EN, Damaraju LV, et al. Role of anti-PF4/heparin antibodies in recurrent thrombotic events after coronary syndromes. Semin. Thromb. Hemost. 2004;30:347–350
  74. Bennett-Guerrero E, Slaughter TF, White WD, et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J. Thorac. Cardiovasc. Surg. 2005;130:1567–1572
  75. Pena dela Vega L, Miller RS, Benda MM, et al. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: A population-based study. J. Lab. Clin. Med. 2005;80:995–1000
  76. Gluckman TJ, Segal JB, Fredde NL, et al. Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. Am. J. Cardiol. 2005;95:744–747
  77. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 2001;344:1286–1292
  78. Lubenow N, Kempf R, Eichner A, et al. Heparin-induced thrombocytopenia: Temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest. 2002;122:37–42
  79. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997;336:973–979
  80. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–466

 Some of the work described in this article was supported from 1993 until the present by operating grants from the Heart and Stroke Foundation of Ontario (A2449, T2967, B3763, T4502, T5207).

PII: S0887-7963(06)00029-0

doi: 10.1016/j.tmrv.2006.05.001

Transfusion Medicine Reviews
Volume 20, Issue 4 , Pages 259-272 , October 2006

Article Tools

* Image Usage & Resolution